Pharmacokinetics of the time-dependent elimination of all-trans-retinoic acid in rats
- 1 March 2004
- journal article
- research article
- Published by Springer Nature in AAPS PharmSci
- Vol. 6 (1) , 1-9
- https://doi.org/10.1208/ps060101
Abstract
The time-dependent elimination kinetics of all-transretinoic acid (ATRA) has been associated with autoinduction of its metabolism and has led to the hypothesis that rapid development of acquired clinical resistance to ATRA may be prevented by coadministration of metabolic inhibitors. This study in rats was performed to investigate the pharmacokinetics and onset of timedependent elimination of ATRA, with the purpose of establishing an animal model suitable for in vivo preclinical studies of compounds capable of inhibiting ATRA metabolism. After the intravenous (IV) bolus administration of single doses of ATRA (1.60 mg kg−1 and 0.40 mg kg−1), the plasma concentration-time curves showed an accelerated decline at 180 minutes after dosing. The plasma clearance (Cl) of ATRA, determined after IV administration of a second dose (1.60 mg kg−1), at 180 minutes was greater than Cl after a single dose, thus indicating the existence of a time-dependent elimination process detectable 180 minutes after administration of the first dose. Such time-dependent elimination was confirmed by means of an IV constant-rate infusion of 0.48 mg h−1 kg−1 of ATRA during 10 hours. Peak plasma ATRA concentration was achieved at 180 minutes, after which the plasma concentration decreased to reach a much lower apparent steady-state drug concentration at 420 minutes. The area under the plasma concentration-time curve (AUC) obtained after oral administration of a second ATRA dose (1.60 mg kg−1) was ∼8% of the AUC obtained after a single oral dose; consistent with a time-dependent increase in the elimination of ATRA, as was observed after IV administration.Keywords
This publication has 22 references indexed in Scilit:
- Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers.2003
- Clinical applications of retinoids in cancer medicine.2003
- Retinoic acid resistance in acute promyelocytic leukemiaLeukemia, 2002
- Phase I trial of interferon α2b and liposome‐encapsulated all‐trans retinoic acid in the treatment of patients with advanced renal cell carcinomaCancer, 2002
- Cloning of rat cytochrome P450RAI (CYP26) cDNA and regulation of its gene expression by all-trans-retinoic acid in vivoArchives of Biochemistry and Biophysics, 2002
- All trans retinoic acid in acute promyelocytic leukemiaOncogene, 2001
- All-trans retinoic acid and interferon-α in the treatment of a patient with resistant metastatic osteosarcomaCancer, 2000
- Clinical Pharmacokinetics of TretinoinClinical Pharmacokinetics, 1997
- Dose-Dependent Pharmacokinetics of All-trans-Retinoic AcidJNCI Journal of the National Cancer Institute, 1992
- Pharmacokinetic Absorption Plots from Oral Data Alone or Oral/Intravenous Data and An Exact Loo–Riegelman EquationJournal of Pharmaceutical Sciences, 1983